SPECIFIC ANTIDOTES FOR DIRECT ORAL ANTICOAGULANTS

  • Vipa Thammatinno Department of Pharmacy, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok
Keywords: specific antidote, DOACs, idarucizumab, andexanet alfa, ciraparantag

Abstract

Currently, the use of Direct Oral Anticoagulants (DOACs) has become more common place since this group of drugs was developed to overcome the limitations of warfarin. However, inappropriate use of DOACs may increase the risk of bleeding. There is a need for an antidote which reverses this risk of bleeding from use or overuse of DOACs as well as to prevent bleeding associated with DOACs in patients undergoing emergency or elective surgery. Management guidelines are based on the level of urgency, severity and/or place of bleeding. Unfortunately, there is limited information regarding this reversal approach. Currently, specific antidotes for DOACs are being developed and approved for clinical use. The first approved specific antidote, idarucizumab, is indicated to reverse dabigatran’s effects in patients with a life-threatening haemorrhage or in need of urgent surgery. However, idarucizumab does not antagonize effects of other DOACs. In 2018, Andexanet alfa was approved by the USFDA for the reversal of apixaban’s and rivaroxaban’s effects. Lastly, ciraparantag, the universal antidote which reverses effects of both factor Xa inhibitors and factor IIa inhibitors, is under investigation.

Downloads

Download data is not yet available.

References

The American Society of Health-System Pharmacists (ASHP). Managing and reversing direct oral anticoagulants: a discussion guide [cited 2020 Dec 15]. Available from: http://ashpadvantagemedia.com/doacresources/files/doacresources-discussion-guide.pdf

Schwarb H, Tsakiris DA. New direct oral anticoagulants (DOAC) and their use today. Dent J. 2016;4-5.

Burnett A, Siegal D, Crowther M. Specific antidotes for bleeding associated with directoral anticoagulants. BMJ. 2017;357:j2216

Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121:3554-62.

PRAXBIND® (idarucizumab) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2015.

Shih AW, Crowther MA. Reversal of direct oral anticoagulants: a practical approach. Hematology Am Soc Hematol Educ Program. 2016;612-9.

Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015;386:680-90.

Glund S, Moschetti V, Norris S, Stangier J, Schmohl M, van Ryn J, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015;113:943-51.

Pollack CV, Reilly PA, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511-20.

Pollack CV, Reilly P, Eikelboom J, Glund S, Gruenenfelder F, Bernstein R, et al. Idarucizumab for reversal of the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions. J Am Coll Cardiol. 2016;67(13 Suppl):664.

ANDEXXA® (andexanet alfa) [package insert]. South San Francisco, USA: Portola Pharmaceuticals, Inc; 2017 [cited 2021 Jan 8]. Available from: https://www.fda.gov/media/ 113279/download

Crowther M, Mathur V, Kitt M, Lu G, Pamela BC, Hollenbach S, et al. A phase 2 randomized, double-blind, placebo-controlled trial of PRT064445 (andexanet alfa), a novel, universal antidote for direct and indirect factor Xa inhibitors. Blood. 2014;124(21):4269.

Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19:446-51.

Siegal DM, Connolly SJ, Conley PB, Wiens BL, Mathur VS, Castillo J, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413-24.

Clinicaltrials.gov [Database on the internet]. A study in patients with acute major bleeding to evaluate the ability of andexanet alfa to reverse the anticoagulation effect of direct and indirect oral anticoagulants [cited 2021 Jan 8]. Available from: https://www.clinicaltrials.gov/ct2/show/ NCT02329327?term=andexanet&rank=3

Connolly SJ, Crowther M, Eikelboom JW, Gibson M, Curnutte JT, Lawrence JH, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380:1326-35.

Laulicht B, Bakhru S, Lee C, Baker C, Jiang X, Mathiowitz E, et al. Small molecule antidote for anticoagulants. Circulation [Internet]. 2012 [cited 2021 Jan 20]; 126:A11395. Available from: http://circ.ahajournals.org/cgi/content/ meeting_abstract/126/21_MeetingAbstracts/A11395?sid=e9490841-a812-42d8-ab48-2d661cf7fccf

Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014; 371:2141-2.

Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso MA, Brown K, et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost. 2017;117:238–45.

Clinicaltrials.gov [Database on the internet]. Study of ciraparantag for reversal of anticoagulation induced by apixaban or rivaroxaban in healthy adults [cited 2021 Jan 29]. Available from: https://clinicaltrials.gov/ct2/show/ NCT04593784

Sewell JH, Williams L, McKnight E, Nguyen A, Sarac M, et al. What is the role of andexanet alfa in the reversal of anticoagulant effects?, JAAPA. 2021;34(1):8-9.

Published
2021-07-13
Section
Review Articles